Evaluation of The Cost Saving Potential of Introducing An Etanercept Biosimilar (Benepali®) For The Treatment of All Licensed Adult Etanercept Indications In The UK
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.1083
https://www.valueinhealthjournal.com/article/S1098-3015(16)32449-4/fulltext
Title :
Evaluation of The Cost Saving Potential of Introducing An Etanercept Biosimilar (Benepali®) For The Treatment of All Licensed Adult Etanercept Indications In The UK
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32449-4&doi=10.1016/j.jval.2016.09.1083
First page :
A533
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1014